{
    "clinical_study": {
        "@rank": "68863", 
        "arm_group": {
            "arm_group_label": "lurbinectedin (PM01183) / doxorubicin", 
            "arm_group_type": "Experimental", 
            "description": "Doxorubicin 50 mg/m2 administered as an intravenous (i.v.) bolus followed by PM01183 4.0 mg flat dose (FD) as a 1-hour i.v. infusion on Day 1 every 3 weeks"
        }, 
        "brief_summary": {
            "textblock": "Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in\n      Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected\n      Advanced Solid Tumors to determine the maximum tolerated dose (MTD) and the recommended dose\n      (RD) of PM01183 in combination with doxorubicin, to characterize the safety profile and\n      feasibility of this combination, to characterize the pharmacokinetics (PK) of this\n      combination, to obtain preliminary information on the clinical antitumor activity and to\n      evaluate the pharmacogenomics (PGx) in tumor samples of patients exposed to PM01183 and\n      doxorubicin at the RD in order to assess potential markers of response and/or resistance."
        }, 
        "brief_title": "Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Endometrial Adenocarcinomas", 
            "Neuroendocrine Tumors", 
            "Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma", 
                "Neuroendocrine Tumors", 
                "Endometrial Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study has currently met its primary end point and is now recruiting patients to be\n      treated at the RD expansion cohort of selected tumor types, specifically: endometrial\n      adenocarcinomas, neuroendocrine tumors, and small-cell lung cancer (SCLC)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Voluntarily written informed consent\n\n          -  Age: between 18 and 75 years (both inclusive).\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) \u2264 1.\n\n          -  Life expectancy \u2265 3 months.\n\n          -  Patients with a histologically/cytologically confirmed diagnosis of advanced disease\n             of any of the following tumors:\n\n               1. Breast cancer\n\n               2. Soft-tissue sarcoma\n\n               3. Primary bone sarcomas.\n\n               4. Gynecologic tumors (endometrial adenocarcinomas, epithelial ovarian cancer...)\n\n               5. Hepatocellular carcinoma\n\n               6. Gastroenteropancreatic neuroendocrine tumors\n\n               7. Small cell lung cancer (SCLC)\n\n               8. Gastric cancer\n\n               9. Bladder cancer\n\n              10. Adenocarcinoma of unknown primary site\n\n          -  At least three weeks since the last anticancer therapy, including radiotherapy\n\n          -  Adequate bone marrow, renal, hepatic, and metabolic function\n\n          -  Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated\n             acquisition (MUGA) scan within normal range (according to institutional standards).\n\n          -  Women of childbearing potential must have a negative serum pregnancy test before\n             study entry. Both women and men must agree to use a medically acceptable method of\n             contraception throughout the treatment period and for six weeks after discontinuation\n             of treatment\n\n        Exclusion Criteria:\n\n          -  Concomitant diseases/conditions:\n\n               -  History or presence of unstable angina, myocardial infarction, congestive heart\n                  failure, or clinically significant valvular heart disease within last year.\n\n               -  Symptomatic or any uncontrolled arrhythmia\n\n               -  Ongoing chronic alcohol consumption, or cirrhosis\n\n               -  Active uncontrolled infection.\n\n               -  Known human immunodeficiency virus (HIV) infection.\n\n               -  Any other major illness that, in the Investigator's judgment\n\n          -  Brain metastases or leptomeningeal disease involvement.\n\n          -  Men or women of childbearing potential who are not using an effective method of\n             contraception\n\n          -  Patients who have had radiation therapy in more than 35% of the bone marrow.\n\n          -  History of previous bone marrow and/or stem cell transplantation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "73", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970540", 
            "org_study_id": "PM1183-A-003-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "lurbinectedin (PM01183) / doxorubicin", 
                "description": "lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.", 
                "intervention_name": "lurbinectedin (PM01183)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "lurbinectedin (PM01183) / doxorubicin", 
                "description": "Doxorubicin 50 mg injectable solution", 
                "intervention_name": "Doxorubicin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Doxorubicin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "lurbinectedin", 
            "PM01183", 
            "tumors", 
            "cancer", 
            "Pharma Mar"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "location": [
            {
                "contact": {
                    "email": "emiliano.calvo@start.stoh.com", 
                    "last_name": "Emiliano Calvo, MD", 
                    "phone": "91 756 78 00"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Madrid Sanchinarro"
                }, 
                "investigator": {
                    "last_name": "Emiliano Calvo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "martin.foster@cancer.ucl.ac.uk", 
                    "last_name": "Martin Forster, MD", 
                    "phone": "+44 0845 155 5000"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "UCLH (University College London Hospitals)"
                }, 
                "investigator": {
                    "last_name": "Martin Forster, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors", 
        "overall_official": {
            "affiliation": "Pharma Mar", 
            "last_name": "Sergio Szyldergemajn, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The RD will be the highest dose level explored in which less than one third of evaluable patients experience a Dose Limiting Toxicity (DLT) during Cycle 1.", 
            "measure": "Recommended Dose (RD)", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The dose-exposure relationships for maximum plasma concentration (Cmax) and area under the curve (AUC) will be evaluated.", 
                "measure": "Pharmacokinetics (PK) characterisation", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Pharmacogenomics will be evaluated in order to determine predictive/prognostic markers of response and/or resistance to PM01183 and doxorubicin.", 
                "measure": "Pharmacogenomic (PGx) analysis", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Recommended Dose expansion is ongoing in selected tumor types in order to confirm preliminary evidence of activity, specifically the study is recruiting patients with neuroendocrine tumors (NETs), or endometrial adenocarcinomas or SCLC (with less than 2 systemic chemotherapy-containing prior lines of therapy)", 
                "measure": "Preliminary antitumor efficacy", 
                "safety_issue": "No", 
                "time_frame": "42 months"
            }
        ], 
        "source": "PharmaMar", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PharmaMar", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}